CEPI has committed up to $50 million to Moderna for the preclinical development and Phase 1 clinical testing of its mRNA-based Bundibugyo ebolavirus (BDBV) vaccine candidate. This funding is part of a larger $60 million initiative by CEPI to accelerate BDBV vaccine development. The investment will also support Moderna's manufacturing scale-up and preparation for future Phase 2/3 trials.